Ipamorelin is a short peptide sequence capable of binding to the ghrelin/growth hormone secretagogue receptor. It is one of the most selective growth hormone (GH) secretagogues known and has been shown in laboratory studies to have no effect on ACTH, prolactin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, or cortisol release [1]. Given its high level of specificity, ipamorelin has been of interest in research both as a therapeutic in and of itself as well as a model peptide for understanding how selectivity in GH receptor binding is achieved. Its presence plays a key role in the overall growth and repair of musculoskeletal tissue.
Highly Selective GHRP for Growth Hormone Research
Ipamorelin is a selective growth hormone secretagogue and potent ghrelin receptor agonist, offering researchers a precise tool for studying growth hormone pathways without affecting cortisol or prolactin levels. This research peptide provides clean growth hormone stimulation for controlled studies.
Research Applications:
- Selective growth hormone studies
- Ghrelin receptor research
- Metabolic pathway investigations
- Bone health mechanism studies
- Insulin regulation research
Technical Details:
- Pentapeptide structure
- High receptor selectivity
- Minimal side pathway activation
- Research-grade preparation
For in-vitro research applications only.
Ipamorelin 5mg - Selective Growth Hormone Secdorelin 10mg - GnRH Research Analog
- Typical dosages can range, but commonly it’s 2mg per vial, which can be reconstituted with sterile water.
- The peptide is typically administered via subcutaneous injection.
- The dosing regimen often involves one injection per week, as it has a prolonged half-life (due to the DAC component).
- As with any peptide, there could be risks, such as injection site reactions, water retention, or possible changes in insulin sensitivity.
- It’s important to monitor health regularly and consult with a healthcare provider, especially if using for long-term purposes.